SARS-CoV-2 infection of airway organoids reveals conserved use of Tetraspanin-8 by Ancestral, Delta, and Omicron variantsArticle Published on 2023-03-142023-06-14 Journal: Stem Cell Reports [Category] Fulltext, 신종인플루엔자, [키워드] Airway organoids cell composition H1N1 SARS-CoV-2 single cell RNAseq spectral flow Therapeutics TSPAN8 variants virus. [DOI] 10.1016/j.stemcr.2023.01.011 PMC 바로가기
In silico analysis of genomic landscape of SARS-CoV-2 and its variant of concerns (Delta and Omicron) reveals changes in the coding potential of miRNAs and their target genesArticle Published on 2023-02-152023-07-11 Journal: Gene [Category] COVID19(2023년), [키워드] Delta miRNA. omicron pathway SARS-CoV-2 target gene variants [DOI] 10.1016/j.gene.2022.147097 PMC 바로가기
Research progress of biosensors for detection of SARS-CoV-2 variants based on ACE2Article Published on 2023-01-012022-11-15 Journal: Talanta [Category] SARS, 변종, 치료기술, [키워드] Accuracy ACE2 acute respiratory syndrome addition antibody biosensor biosensors caused Cell cells complex coronavirus coronavirus disease COVID-19 detect detection Diagnosis drug evaluated gold standard Health increase Interaction modulate Mutation Novel coronavirus pandemic Prevent receptor RT-PCR SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2 variant SARS-CoV-2 variants SARS-CoV-2. the spike protein time-consuming variants Variation virus virus mutations [DOI] 10.1016/j.talanta.2022.123813 PMC 바로가기
Strategies to tackle SARS-CoV-2 Mu, a newly classified variant of interest likely to resist currently available COVID-19 vaccines현재 사용 가능한 COVID-19 백신에 저항할 가능성이 있는 새로 분류된 관심 변종인 SARS-CoV-2 Mu에 대처하기 위한 전략Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), MERS, SARS, 변종, 유전자 메커니즘, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration adopted approach B.1 lineage B.1.621 BNT161b2 booster dose Characteristics coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccine COVID-19 vaccine development Evidence exacerbated Genetic genomic Genomic surveillance global mass vaccination Health implementation infections Intervention Lineage mass vaccination Mu variant mutations Neutralizing non-pharmaceutical interventions (NPIs) NPIs potential risk public health measure public health measures Recombination reported required respiratory restrict SARS-CoV-2 SARS-CoV-2 B.1.621 SARS-CoV-2 virus sera shown Strains Strategy sub-lineage B.1.621.1 Surveillance survivor the SARS-CoV-2 virus therapeutic threat vaccination Vaccine vaccine breakthrough. Vaccine development variant variants [DOI] 10.1080/21645515.2022.2027197 PMC 바로가기 [Article Type] Article
Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study건강한 성인에서 이종 및 동종 불활성화 및 아데노바이러스 매개 COVID-19 백신 요법의 안전성 및 면역원성: 전향적 코호트 연구Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] Adults adverse event adverse events Antibody Response AstraZeneca ChAdOx1 ChAdOx1-S circulating variants combinations CoronaVac country COVID-19 COVID-19 vaccine COVID-19 vaccines dose doses Efficacy Evidence evidence of followed by group groups healthy Heterologous heterologous adenoviral vector heterologous vaccine homologous IgA response immune response immune responses immunized immunogenicity inactivated Inactivated vaccine interferon gamma Mild neutralizing activities Neutralizing activity prospective cohort study reactogenicity Receptor-binding domain referred to regimen Safety Serious Adverse Event Serious Adverse Events supply shortage vaccination Vaccine variants variants of concern Viral viral vectored. wild-type [DOI] 10.1080/21645515.2022.2029111 PMC 바로가기 [Article Type] Article
The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review감염, 중증도, 입원 및 사망률 감소에 대한 COVID-19 백신의 효능 및 효과: 체계적인 검토Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), SARS, 변종, [키워드] accelerated approved B.1.1.7 B.1.351 B.1.351 variants COVID-19 COVID-19 pandemic COVID-19 vaccine COVID-19 vaccines database disease transmission effective Effectiveness Efficacy effort growth Hospitalization identify inclusion criteria Infection infections Mortality Pfizer Pfizer/BioNTech populations reduced reducing regimen required Seven severity systematic literature search systematic review Vaccine Vaccine development vaccine. Vaccines variants was performed [DOI] 10.1080/21645515.2022.2027160 PMC 바로가기 [Article Type] Article
COVID-19 vaccine uptake and effectiveness in adults aged 50 years and older in Wales UK: a 1.2m population data-linkage cohort approach영국 웨일즈에서 50세 이상 성인의 COVID-19 백신 섭취 및 효과: 120만 인구 데이터 연결 코호트 접근법Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), SARS, 변종, [키워드] 95%CI Adult affected Alpha approach BNT162b2 ChAdOx1 ChAdOx1 vaccine ChAdOx1 vaccines Characteristics Cohort collected data Coverage COVID-19 COVID-19 vaccine COVID-19 vaccines death Delta dose doses Effectiveness estimate first dose followed by Hospital admission immunization Infection linkage of BNT162b2 Older outcome outcomes PCR positive PCR positive SARS-CoV-2 infection post vaccination predominant SARS-CoV-2 SARS-COV-2 infection schedule second dose Seven strain vaccination vaccination. Vaccine variants Wales [DOI] 10.1080/21645515.2022.2031774 PMC 바로가기 [Article Type] Article
Impact of SARS-CoV-2 variants on mobility and air pollution in the United KingdomArticle Published on 2022-12-102022-11-16 Journal: The Science of the total environment [Category] COVID19(2023년), SARS, 변종, 치료기술, [키워드] activity affecting Algorithm Alpha baseline baseline level baseline levels contagiousness COVID-19 COVID-19 case death Delta event Government Immunity Impact Increases measure NO(2) normality Pollution prevalent Public public health reduced remained Result returned SARS-CoV-2 variant significant increase significantly social contact Spread Traffic Traffic. United Kingdom variant variants virus wildtype [DOI] 10.1016/j.scitotenv.2022.158279 PMC 바로가기
SARS-CoV-2 shedding dynamics and transmission in immunosuppressed patients면역 억제 환자의 SARS-CoV-2 발산 역학 및 전파Article Published on 2022-12-012022-09-11 Journal: Virulence [Category] COVID19(2023년), SARS, 변종, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus adjust analysed anatomic site characterized collected conducted coronavirus Diagnosis Diversity dominant E484K first positive fitness genetic change Genome genomic Host hosts household transmission Immunosuppressed immunosuppressed patient immunosuppressed patients in urine in vivo Infection Interaction knowledge long-term viral shedding mother mutate Mutation mutation dynamics N501Y occurred P681R Patient replicate residue residues SARS-CoV-2 SARS-CoV-2 evolution selective Sequencing severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 specific treatment Spike protein spread to Substitution temporal dynamics Transmission two patients Urine variant variant of concern variants variants of concern virus whole genome Whole genome sequencing whole genome sequencing. whole-genome sequencing [DOI] 10.1080/21505594.2022.2101198 PMC 바로가기 [Article Type] Article
Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Article Published on 2022-12-012022-11-15 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 비임상, 진단, 치료기술, 치료제, [키워드] acute respiratory syndrome Beta Blood caused clinically Concentration coronavirus COVID-19 creatine phosphokinase CT-P63 deaths declining Delta demonstrated detectable dose double-blind evaluated groups healthy volunteer Immunity in vitro in vivo Infection Infectious virus lung monoclonal monoclonal antibody morbidity and mortality mutated variant Neutralizing Neutralizing activity neutralizing antibody neutralizing antibody. omicron pandemic parallel-group participant peaked phase Placebo placebo-controlled Preclinical prevalent Prophylactic Randomized reduced respiratory tract Safe SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants of concern Serious Adverse Events significantly single ascending dose study drug TEAE titre Tolerability Transgenic mouse treated Treatment treatment-emergent adverse event vaccination variants variants of SARS-CoV-2 wild-type [DOI] 10.1080/22221751.2022.2117094 PMC 바로가기